LAVA Therapeutics N.V. announced Ed Smith, chief financial officer has resigned to pursue other interests, effective as of May 17, 2022. He may serve in a consulting capacity to support the Company's transition. The Company has commenced a search for Mr. Smith's permanent replacement.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.945 USD | -1.27% | -18.59% | +20.57% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.57% | 51.8M | |
+35.80% | 51.51B | |
-6.32% | 39.03B | |
+34.94% | 38.91B | |
-10.62% | 26.68B | |
+12.62% | 26.13B | |
-15.89% | 19.91B | |
+42.52% | 13.71B | |
+30.74% | 12.38B | |
-3.30% | 11.74B |
- Stock Market
- Equities
- LVTX Stock
- News LAVA Therapeutics N.V.
- LAVA Therapeutics N.V. Announces the Resignation of Ed Smith as Chief Financial Officer